Ibrutinib

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4445 publications

Corrigendum to "Disappearance of the Defining Organized Ultrastructural Lesion in Chronic Lymphocytic Leukemia-Associated Monoclonal Immunotactoid Glomerulopathy After Ibrutinib Therapy" [Kidney International Reports Volume 11, Issue 8, August 2026, 106643].

Corrigendum to "Disappearance of the Defining Organized Ultrastructural Lesion in Chronic Lymphocytic Leukemia-Associated Monoclonal Immunotactoid Glomerulopathy After Ibrutinib Therapy" [Kidney International Reports Volume 11, Issue 8, August 2026, 106643].

Journal: Kidney international reports

Published: August 29, 2026

Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.

Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 27, 2026

Correction to: DLBCL-microenvironment interactions: cytokine profiling and ECM mediated ibrutinib resistance in a 3D bone-based model.

Correction to: DLBCL-microenvironment interactions: cytokine profiling and ECM mediated ibrutinib resistance in a 3D bone-based model.

Journal: Medical oncology (Northwood, London, England)

Published: August 26, 2026

Polymeric nanoparticle platforms for ibrutinib delivery: tackling solubility, CYP3A4-mediated metabolism, and resistance to facilitate BTK-targeted therapy in solid tumours.

Polymeric nanoparticle platforms for ibrutinib delivery: tackling solubility, CYP3A4-mediated metabolism, and resistance to facilitate BTK-targeted therapy in solid tumours.

Journal: Therapeutic delivery

Published: August 25, 2026

Ibrutinib tablet splitting as a practical strategy for dose reduction in the management of drug-drug interactions.

Ibrutinib tablet splitting as a practical strategy for dose reduction in the management of drug-drug interactions.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: August 20, 2026

Bilateral optic neuropathy secondary to chronic lymphocytic leukaemia infiltration.

Bilateral optic neuropathy secondary to chronic lymphocytic leukaemia infiltration.

Journal: BMJ case reports

Published: August 20, 2026

Pirtobrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Systematic Review.

Pirtobrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Systematic Review.

Journal: American journal of clinical oncology

Published: August 13, 2026

Pathophysiological Drivers of Mast Cell Activation Syndrome and Implications for Treatment.

Pathophysiological Drivers of Mast Cell Activation Syndrome and Implications for Treatment.

Journal: Fortune journal of health sciences

Published: August 13, 2026

Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia.

Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 07, 2026

Recent advances and future perspectives in the treatment of chronic lymphocytic leukemia

Recent advances and future perspectives in the treatment of chronic lymphocytic leukemia

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: August 03, 2026

Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States.

Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States.

Journal: Future oncology (London, England)

Published: July 30, 2026

Mechanisms of resistance to BTK inhibitors in B cell malignancies and emerging targeted strategies.

Mechanisms of resistance to BTK inhibitors in B cell malignancies and emerging targeted strategies.

Journal: Molecular therapy. Oncology

Published: July 28, 2026

Showing 1-12 of 4,445

Last Updated: 09/26/2026